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S U M M A R Y
Objectives: In the post-pandemic period 2010–2015, seasonal inﬂuenza A(H3N2) virus predominated in
Hangzhou, southeast of China, with an increased activity and semi-annual seasons. This study utilized
HA virus gene segment sequences to analyze the divergence date and vaccine strain match of human
inﬂuenza A(H3N2) virus from systematic inﬂuenza surveillance in Hangzhou.
Methods: Virological and serological analyses of 124 representative A(H3N2) viruses from prospective
studies of systematic surveillance samples were conducted to quantify the genetic and antigenic
characteristics and their vaccine strain match.
Results: Bayesian phylogenetic inference showed that two separate subgroups 3C.3 and 3C.2 probably
diverged from group 3C in early 2012 and then evolved into groups 3C.3a and 3C.2a, respectively, in the
2014/15 inﬂuenza season. Furthermore, high amino acid substitution rates of the HA1 subunit were
found in A(H3N2) group 3C.2a variants, indicating that increased antigenic drift of A(H3N2) group 3C.2a
virus is associated with a vaccine mismatch to the 2015/16 vaccine reference strain Switzerland/
9715293/2013 (group 3C.3a).
Conclusions: A portion of the group 3C.2a isolates are not covered by the current A(H3N2) vaccine strain.
These ﬁndings offer insights into the emergence of group 3C.2a variants with epidemic potential in the
imminent inﬂuenza seasons.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Inﬂuenza viruses are important causative pathogens of
respiratory tract infections in humans and animals globally and
occasionally give rise to human pandemics. Currently circulating
subtypes of human seasonal inﬂuenza viruses are A(H1N1)pdm09,
A(H3N2), and B-Yamagata lineage, which are the three compo-
nents of the annual trivalent vaccine recommended by the World
Health Organization (WHO) Collaborating Centers for Reference
and Research on Inﬂuenza (WHOCCs).1 A(H3N2) evolves signiﬁ-
cantly faster than the other subtypes,2 and thus could spread more
quickly; it usually causes more severe outcomes among risk* Corresponding author. Tel.: +86 571 8517 6761.
E-mail address: 10407030@zju.edu.cn (J. Li).
http://dx.doi.org/10.1016/j.ijid.2015.09.013
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).groups.3 Season by season, continuous antigenic drift occurs in
these viruses, altering their ability to cause infection and be
transmitted among hosts. The circulating viruses escape the
human immune response by having differences from the vaccine
strains, and this can lead to vaccine failure.4 In response to the
threats posed by variants, the recommended seasonal A(H3N2)
vaccine strain for use in the northern hemisphere seasons has been
replaced by the WHO four times in the last 5 years.1
Hangzhou is a city of national tourism with a registered
population of 8.9 million. It is located on the south wing of the
Yangtze River Delta and has a humid, subtropical climate,
facilitating the airborne survival and transmission of inﬂuenza
viruses.5 A(H3N2) viruses emerged in the post-pandemic period
and have predominated in Hangzhou since August 2010. Previous
genetic analysis of the very recent Hangzhou A(H3N2) strains
indicated the emergence of escape variants with antigenic drift inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
J. Li et al. / International Journal of Infectious Diseases 40 (2015) 17–2418the HA1 domain.6 However, the lack of a comprehensive
comparison of prevalent isolates with vaccine strains has
hampered attempts to estimate the potential vaccine efﬁcacy
(VE) and to reconstruct the origins of these epidemics in the
locality. This study was performed to quantify the genetic diversity
and antigenic dynamics of seasonal A(H3N2) viruses in Hangzhou
using a dataset of 124 isolates from more than 60 months of
systematic surveillance. This was done in order to determine the
possibility of more severe outbreaks in the near future.
2. Materials and methods
2.1. Systematic inﬂuenza surveillance
The surveillance was conducted from January 2010 to March
2015 among patients with an inﬂuenza-like illness (ILI) admitted
to two tertiary hospitals in Hangzhou, China. Nasal swabs,
oropharyngeal swabs, and/or tracheal aspirate samples were
collected (N = 8958) with the informed consent of the patients
or their spouses (Figure 1A). These were sent to the Hangzhou
Center for Disease Control and Prevention for diagnosis within
24 h.
2.2. Virus detection and subtype identiﬁcation
Viral RNA was extracted directly from the supernatant of the
clinical sample using the RNeasy Mini Kit, as per the manufac-
turer’s instructions (Qiagen, Germany). This was tested for the
presence of seasonal inﬂuenza virus using a diagnostic real-time
reverse transcription PCR (RT-PCR) on an ABI 7500 instrument
(Applied Biosystems, USA) following the WHO guidelines.7 Swab
materials of positive samples were then inoculated into Madin–
Darby canine kidney (MDCK) cells for virus isolation.Figure 1. The prevalence of seasonal inﬂuenza virus in Hangzhou, China. (A) The num
surveillance period, from January 2010 to March 2015. (B) The positive rate of seasona
December 2010; E2, January 2012 to March 2012; E3, July 2012 to September 2012; E4, Ja
2014; E7, January 2015 to March 2015). The annual vaccine candidates recommended by
epidemics. (C) Overlapping images of the positive rates indicate the seasonal distribut2.3. Hemagglutinin (HA) gene sequencing
Of 664 clinical specimens from laboratory-conﬁrmed A(H3N2)
infections, 124 (18.7%) with a high viral load (cycle threshold (Ct)
value <30) were selected randomly from each epidemic for
sequencing (E1, n = 8; E2, n = 9; E3, n = 8; E4, n = 5; E5, n = 54; E6,
n = 22; E7, n = 18). The HA segment was subsequently ampliﬁed by
RT-PCR with the primers described previously, using a PrimeScript
One Step RT-PCR Kit Ver.2 (TaKaRa, Japan).8,9 The amplicons were
sequenced in both directions at Sangon (Shanghai, China). All
sequences were assembled and edited with Lasergene v. 7.1.0
(DNASTAR). The full-length sequences obtained were then deposit-
ed in Global Initiative on Sharing Avian Inﬂuenza Data (GISAID)
databases under accession numbers EPI622591–EPI622714.
2.4. Phylogenetic analysis
Multiple sequence alignment was conducted using Clustal X v.
1.8 combined with reference sequences of A(H3N2) viruses
available in the GISAID databases (the accession numbers are
listed in Table 1). Phylogenetic trees were generated by maximum
likelihood method with bootstrap analysis (1000 replicates) using
the MEGA v. 5.0 program.10 The group numbers were assigned to
achieve consistency with earlier studies.11
In order to assess the extent of divergence between different
groups or clusters, these data were then used to infer the
temporal phylogenies, viral evolution rates, and divergence
dates of A(H3N2) viruses employing a relaxed clock model with
uncorrelated log-normal rate distribution in a Bayesian Markov
chain Monte Carlo (MCMC) framework implemented in BEAST
package v. 1.7.412 and Tracer v. 1.5.0 software. Bayesian
phylogenetic inference was presented graphically using FigTree
v. 1.4.2 application.ber of patients with an inﬂuenza-like illness (ILI) sampled weekly during a 5-year
l inﬂuenza A(H3N2) virus; seven A(H3N2) epidemics are seen (E1, August 2010 to
nuary 2013 to March 2013; E5, July 2013 to February 2014; E6, July 2014 to October
 the WHO during these seasons are also shown, in the same color as the associated
ion of the currently circulating subtypes of human seasonal inﬂuenza viruses.
Table 1
Origin of HA sequence information of reference A(H3N2) strains included in the phylogenetic analysesa
Isolate name Group Accession
number
Collection
date
Originating laboratory Submitting laboratory Authors
A/Stockholm/18/2011 3A EPI326139 2011-Feb-21 Swedish Institute for
Infectious Disease Control
National Institute for Medical
Research
A/England/691/2010 3A EPI319221 2010-Dec-13 Health Protection Agency National Institute for Medical
Research
A/England/259/2011 3B EPI346607 2011-Nov-16 Health Protection Agency National Institute for Medical
Research
A/Maryland/02/2012 3B EPI358041 2012-Jan-18 Maryland Department of
Health and Mental Hygiene
Centers for Disease Control
and Prevention
A/Victoria/361/2011 3C EPI349106 2011-Oct-24 Melbourne Pathology WHO Collaborating Centre
for Reference and Research
on Inﬂuenza
Deng YM, Caldwell N,
Iannello P, Komadina N
A/Texas/50/2012 3C.1 EPI391247 2012-Apr-15 Texas Department of State
Health Services–Laboratory
Services
Centers for Disease Control
and Prevention
A/Norway/1903/2014 3C.2 EPI539623 2014-May-20 WHO National Inﬂuenza
Centre
National Institute for Medical
Research
A/Hong_Kong/5738/ 2014 3C.2a EPI539806 2014-Apr-30 Government Virus Unit National Institute for Medical
Research
A/Finland/385/2013 3C.3 EPI502957 2013-Dec-11 National Institute for Health
and Welfare
National Institute for Health
and Welfare
Ikonen N, Haanpaa M
A/Switzerland/ 9715293/2013 3C.3a EPI530687 2013-Dec-6 Hoˆpital Cantonal
Universitaire de Gene`ve
National Institute for Medical
Research
A/Quebec/44/2014 3C.3x EPI573951 2014-Dec-8 Other database import Skowronski D, Chambers C,
Sabaiduc S, De Serres G,
Dickinson J, Winter A, Drews
S, Fonseca K, Charest H,
Gubbay J, Petric M, Krajden
M, Kwindt T, Martineau C,
Eshaghi A, Bastien N, Li Y,
Skowronski DM, Dickinson
JA, Winter AL, Gubbay JB,
Kwindt TL
A/Serbia/71/2011 4 EPI326115 2011-Jan-6 Institute of Immunology and
Virology Torlak
National Institute for Medical
Research
A/Alabama/05/2010 5 EPI278805 2010-Jul-13 US Air Force School of
Aerospace Medicine
Centers for Disease Control
and Prevention
A/Victoria/802/2012 EPI379585 2012-May-9 Austin Health WHO Collaborating Centre
for Reference and Research
on Inﬂuenza
Deng YM, Iannello P, Caldwell
N, Jelley L, Komadina N
A/Perth/10/2010 EPI390117 2010-May-25 Other database import Wentworth DE, Dugan V,
Halpin R, Lin X, Bera J, Ghedin
E, Fedorova N, Overton L,
Tsitrin T, Stockwell T,
Amedeo P, Bishop B, Chen H,
Edworthy P, Gupta N, Katzel
D, Li K, Schobel S, Shrivastava
S, Thovarai V, Wang S,
Ramanunninair M, Silverman
J, Devis R, Phan L, Le J,
Pokorny BA, Onodera S,
Fulvini AA, He Y, Kilbourne
ED, Bucher D, Bao Y, Sanders
R, Dernovoy D, Kiryutin B,
Lipman DJ, Tatusova T
A/Victoria/208/2009 EPI232453 2009-Jun-2 WHO Collaborating Centre
for Reference and Research
on Inﬂuenza
Centers for Disease Control
and Prevention
A/IOWA/19/2010 6 EPI335923 2010-Dec-30 Iowa State Hygienic
Laboratory
Centers for Disease Control
and Prevention
A/Maine/07/2012 7 EPI376509 2012-May-21 Maine Health and
Environmental Testing
Laboratory
Centers for Disease Control
and Prevention
A/Perth/16/2009 EPI211334 2009-Apr-7 WHO Collaborating Centre
for Reference and Research
on Inﬂuenza
Centers for Disease Control
and Prevention
A/Norway/1330/2010 2 EPI302231 2010-Dec-3 WHO National Inﬂuenza
Centre
National Institute for Medical
Research
A/Norway/1186/2011 1 EPI326137 2011-Mar-16 Norwegian Institute of Public
Health
National Institute for Medical
Research
A/California/ VRDL277/2009 EPI274218 2009-Apr-30 Other Database Import The NIAID Inﬂuenza Genome
Sequencing Consortium
A/Brisbane/10/2007 EPI165489 2007-Feb-6 Other Database Import
A/Wisconsin/67/2005 EPI160218 2005-Aug-21 Other Database Import
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Table 1 (Continued )
Isolate name Group Accession
number
Collection
date
Originating laboratory Submitting laboratory Authors
A/California/7/2004 EPI367105 2004-Sep-16 Other Database Import Wentworth DE, Dugan V,
Halpin R, Lin X, Bera J, Ghedin
E, Fedorova N, Overton L,
Tsitrin T, Stockwell T,
Amedeo P, Bishop B, Chen H,
Edworthy P, Gupta N, Katzel
D, Li K, Schobel S, Shrivastava
S, Thovarai V, Wang S,
Ramanunninair M, Silverman
J, Devis R, Phan L, Le J,
Pokorny BA, Onodera S,
Fulvini AA, He Y, Kilbourne
ED, Bucher D, Bao Y, Sanders
R, Dernovoy D, Kiryutin B,
Lipman DJ, Tatusova T
A/Fujian/411/2002 EPI358784 2002-Aug-11 Other database import Galiano M, Johnson BF, Myers
R, Ellis J, Daniels R, Zambon M
WHO, World Health Organization; NIAID, National Institute of Allergy and Infectious Diseases; GISAID, Global Initiative on Sharing Avian Inﬂuenza Data.
a All reference sequences were downloaded from the GISAID database.
J. Li et al. / International Journal of Infectious Diseases 40 (2015) 17–2420Potential recombinant events and breakpoints were also
scanned amongst aligned sequences by different recombination
detection algorithms in RDP4 v. 4.46, such as RDP, GENECONV,
Chimaera, MaxChi, BootScan, SiScan, and 3Seq.13
2.5. Genetic and antigenic analysis
The HA nucleotide and deduced amino acid sequences were
compared within all of the A(H3N2) strains from 2010 to 2015. The
pair-wise sequence identities among 124 Hangzhou A(H3N2)
strains were calculated and plotted on a heat map drawn with
ggplot2 v. 1.0.1 in R package.
An estimate of the relative genetic diversity was obtained by
calculating the p-distance based on the equation p = nd/n.
14 The
numbers of amino acid substitutions on the HA1 subunit of
A(H3N2) variants were counted. The potential VE was estimated
using the formula E = 0.47  2.47  Pepitope; the parameter Pepitope
was calculated using a previously established method.4 Further
antigenic characteristics of isolates were conﬁrmed by hemagglu-
tination inhibition (HI) assay with anti-HA sera of seasonal
A(H3N2) northern hemisphere vaccine components. Serum HI
antibody titers were measured for each isolate using guinea pig red
blood cells and standard HA sera (anti-A/Perth/16/2009-like HA
serum for the 2010–2012 seasons, anti-A/Victoria/361/2011-like
HA serum for the 2012–2013 season, anti-A/Texas/50/2012-like
HA serum for the 2013–2015 seasons, and anti-A/Switzerland/
9715293/2013-like HA serum for the 2015–2016 season; National
Institute for Biological Standards and Control, UK) following WHO
standard procedures.15 To conduct the assay, two-fold serial
dilutions of the sera were prepared and mixed with a speciﬁc
amount of the inﬂuenza virus and then the red blood cells. The HI
test was repeated three times, and the geometric mean titers were
then calculated.
3. Results
3.1. The prevalence of inﬂuenza A(H3N2) viruses
From January 2010 through March 2015, the presence of
inﬂuenza virus RNA in respiratory samples of ILI patients in
Hangzhou was 17.7% (1583/8958): 60.4% (n = 956) were typed as
inﬂuenza A and 39.6% (n = 627) as inﬂuenza B. Of the subtyped
inﬂuenza A viruses, 69.5% (n = 664) were A(H3N2) viruses making
up seven inﬂuenza activity peaks (Figure 1B). The ﬁrst A(H3N2)
epidemic came after the end of the A(H1N1)pdm09 pandemic andcontinued for nearly 6 months until the reemergence and transient
domination of A(H1N1)pdm09 variants in the 2010/11 season.16 In
comparison to subtype A(H1N1)pdm09 and type B viruses,
A(H3N2) has entered its semi-annual seasons with increased
activity since early 2012 (Figure 1C).
3.2. The phylogeny and divergence dates
Comprehensive phylogenetic analysis of the gene encoding
surface antigen HA of A(H3N2) isolates revealed that all of the
Hangzhou strains clustered within the Victoria/208/2009 clade
(Figure 2). The recently circulating viruses were mainly with
genetic group 3, except for the 2010/11 season viruses belonging to
group 5 or 6.
Much greater HA diversity was observed after 2012. The
A(H3N2) viruses formed a large group 3C, but were scattered
into different kinds of clusters, indicating dynamic genetic
evolution and their adaptation to the hosts. Divergence events
depicted on the Bayesian phylogenetic tree show that the group
3C.2 and 3C.3 viruses probably diverged from group 3C in early
2012 (Figure 3), and thus constituted two distinct clusters
respectively.
The emergence of these novel clusters was conﬁrmed by the
initial detection of Hangzhou/A379/2012 (3C.2) and Hangzhou/
A289/2012 (3C.3) strains during epidemic E3 in July 2012
(Figure 2). Following this, group 3C.3 viruses became the
predominant strains, constituting nearly 100% of A(H3N2) viruses
in E4 and 96.3% in E5. The evolution of group 3C.3 into 3C.3a at the
beginning of 2014 might represent a viral adaptation for
continuous circulation in E6 (100%) and E7 (77.8%). On the other
side, 22.2% (4/18) of the early 2015 strains clustered within group
3C.2a, which is considered genetically and antigenically distinct
from group 3C.3a viruses. These typically bear 3 to 7 amino acid
differences at the key antigenic sites of the HA1 domain from the
2015/16 vaccine reference strain Switzerland/9715293/2013
(group 3C.3a) (Figure 2). However, no recombinant event was
found by RDP scanning during this period of seasons.
3.3. The genetic and antigenic characteristics and vaccine strain
match
The results of pair-wise analysis showed that the nucleotide
and amino acid identities were 96.8–100% and 95.6–100%, with the
peak frequency around 99.1% and 98.4%, respectively (Figure 4A).
Signiﬁcant differences in sequence identities among seasons were
Figure 2. Phylogenetic relationships of A(H3N2) viruses on the HA gene. The names of the isolates are indicated with different colors according to the season they belong to,
and the genetic clusters to which group they are clustered are also marked. Signature amino acid substitutions are annotated at the node of group 3C.2a in different colors
according to their positions in the epitopes. Only bootstrap values >50% are shown.
J. Li et al. / International Journal of Infectious Diseases 40 (2015) 17–24 21observed through a heat map of the numeric matrix of the identity
values (Figure 4B). Note that the identities of amino acid sequences
were sometimes a bit lower.
The genetic and antigenic characteristics of 124 A(H3N2)
strains were estimated by p-distance and number of amino acid
substitutions, and the potential VE was calculated. Three different
models gave out consistent results (Figure 5). The data indicated
that the replacement of vaccine candidate pushed the vaccine
strain genetically and antigenically closer to the circulating viruses
each time. However, in the following epidemic, the genetic
distance became longer and the predicted VE decreased quicklybecause of the high substitution rates on the HA1 subunit of
A(H3N2) variants.
During E7, several outlying dots were observed, indicating a
signiﬁcant divergence and antigenic differences to the recom-
mended vaccine reference strain. Due to the probable biases of
predicted VE caused by the principal limitations, the results were
conﬁrmed with the HI assay (Figure 5D). Most of the A(H3N2)
viruses emerging in the 2014/15 season reacted well against
antiserum raised to Switzerland/9715293/2013. However, the four
outlying group 3C.2a isolates cross-reacted weakly, representing
an antigenically distinct group 3C.2a from group 3C.3a.
Figure 3. Divergence events based on the HA genes of seasonal inﬂuenza A(H3N2) viruses. The pertinent representative viruses were downloaded from the GISAID database,
including the sequences of WHO-recommended vaccine strains for the northern hemisphere. Arrows indicate the divergence dates when novel subgroups of A(H3N2)
emerged. Node bars represent 95% credible intervals of divergence times. The groups of A(H3N2) variants are differentiated by color in a simple phylogenetic tree.
J. Li et al. / International Journal of Infectious Diseases 40 (2015) 17–24224. Discussion
Inﬂuenza A(H3N2) viruses accounted for 69.5% of inﬂuenza A-
positive cases during the post-pandemic seasons (2010–2015) in
Hangzhou, China. Viral transmission control requires a close
antigenic match between recently circulating viruses and the
vaccine reference strain.17 In China, annual vaccination against
seasonal inﬂuenza viruses is recommended for all persons before
the inﬂuenza season, especially for certain populations at risk of
severe outcomes, including pregnant women, children, and the
elderly.18 Ahead of the next season, to address the lack of genetic
and antigenic characteristics of the epidemic isolates in compari-
son to vaccine strains, virological and serological analyses of
A(H3N2) viruses from prospective studies of systematic surveil-
lance samples in Hangzhou during the post-pandemic period were
conducted.
The monitoring data analysis showed that A(H3N2) has entered
its semi-annual seasons with increased activity since 2012, while
the predominant group 3C viruses have diverged into two separate
paths. Novel subgroups of A(H3N2) emerged following these twoevolution paths in the 2014/15 season. One was group 3C.3a,
including predominant circulating strains in the recent season, and
the other was subgroup 3C.2a, which were occasionally detected at
the beginning of 2015. Viruses with similar sequences in the HA
gene have also been detected sporadically in other countries,19 and
are considered antigenically different from the 2014/15 A/Texas/
50/2012(H3N2)-like clade 3C.1 vaccine reference strain.20,21
However, the complete characteristics of antigenic drift of
A(H3N2) variants in the southeast of China and their vaccine
match have not been reported to date.
The HA protein is one of the major glycoproteins present on the
viral surface and facilitates proper attachment to the host cellular
receptors.22 The HA1 domain contains the ﬁve major antigenic
sites (A–E) acquired for annual evaluation of vaccine effective-
ness.4 Mutations causing antigenic drift of HA are efﬁcient in
evading the host immune response, and are always closely
scrutinized for signs of variation and evolution. In this study,
the VE of the vaccine strains against circulating viruses in the
contemporary period was complicated by antigenic dynamics.
Switzerland/9715293/2013, a group 3C.3a strain, is the 2015/16
Figure 4. A The pair-wise identities of nucleotide and deduced amino acid
sequences among 124 Hangzhou A(H3N2) strains from 2010 to 2015. (B) The
numeric matrix of the identity values of nucleotide (upper triangle) and amino acid
(lower triangle) are plotted on a heat map drawn with ggplot2 v. 1.0.1 in R package.
Figure 5. Genetic and antigenic characterization of A(H3N2) strains from different
seasons. The annual vaccine candidates are listed in the same color as the
corresponding epidemics. (A) Rates of p-distance of the HA gene from vaccine
strains. (B) Amino acid substitutions calculated on the HA1 domain. (C) An estimate
of potential vaccine efﬁcacy (VE) against the circulating strains. (D) Antigenicity
measured by hemagglutination inhibition (HI) assay. Arrows indicate the immune
escape variants of A(H3N2) group 3C.2a strains. Error bars for observations: median
with interquartile range.
J. Li et al. / International Journal of Infectious Diseases 40 (2015) 17–24 23vaccine candidate; this only covers portions of the antigenic types
of circulating A(H3N2) viruses, which may lead to vaccinated
people or those who have previously been infected by the 3C.3a
strain easily being infected by a group 3C.2a variant with distinct
antigenic form. The HI assay was also conducted to conﬁrm that
the VE drop was not an artifact of statistical biases. Consistent
with predicted vaccine mismatch, little cross-reaction was
observed with serum HI antibody titer against A(H3N2) group
3C.2a variants. Although Hammond et al. have suggested that
antigenic relatedness between clade 3C.2a and 3C.3a viruses is
good,23 the present study showed that at least a portion of
subgroup 3C.2a viruses are not covered by the 2015/16 vaccine
reference strain. This potential challenge requires urgent further
study.
Based on the present analysis, little antigenic cross-reaction
was found between group 3C.2a and 3C.3a strains. Thus the 2015/
16 A/Switzerland/9715293/2013-like clade 3C.3a vaccine refer-
ence strain may not offer the desired protection against the
circulating group 3C.2a A(H3N2) viruses in the southeast of China.
Given these ﬁndings, further in-depth investigations should be
considered to determine the increased potential of group 3C.2a
prevalence in the upcoming inﬂuenza seasons. If and when such an
epidemic occurs, people who have been infected by a group 3C.3a
strain in the past will lack immunity to group 3C.2a viruses, and the
2015/16 vaccines against the circulating viruses will also become
less effective.
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